secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001104659-24-027510
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma reports Q4 2023 GAAP net loss $8.5M; non-GAAP net profit $1.4M; YUPELRI net sales up 9% to $60.6M
--------------------------------------------------------------------------------

- Q4 YUPELRI net sales recognized by Viatris grew 9% YoY to $60.6M record high; full-year Viatris collaboration revenue up 18% to $57.2M.
- GAAP net loss of $8.5M in Q4; achieved non-GAAP net profit of $1.4M, driven by YUPELRI growth and expense management.
- Completed $325M capital return program early Jan 2024, reducing shares outstanding by 37%.
- YUPELRI hospital volumes grew 46% YoY, exceeding targets; CYPRESS study enrollment on track for H2 2024.
- Ampreloxetine granted FDA Orphan Drug Designation; investor event planned for Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924027510/0001104659-24-027510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924027510/tm247202d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-027510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer